Research Progress on (18)F-Labeled Agents for Imaging of Myocardial Perfusion with Positron Emission Tomography

Coronary artery disease (CAD) is the leading cause of death in the world. Myocardial perfusion imaging (MPI) plays a significant role in non-invasive diagnosis and prognosis of CAD. However, neither single-photon emission computed tomography nor positron emission tomography clinical MPI agents can a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mou, Tiantian, Zhang, Xianzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154634/
https://www.ncbi.nlm.nih.gov/pubmed/28358340
http://dx.doi.org/10.3390/molecules22040562
Descripción
Sumario:Coronary artery disease (CAD) is the leading cause of death in the world. Myocardial perfusion imaging (MPI) plays a significant role in non-invasive diagnosis and prognosis of CAD. However, neither single-photon emission computed tomography nor positron emission tomography clinical MPI agents can absolutely satisfy the demands of clinical practice. In the past decades, tremendous developments happened in the field of (18)F-labeled MPI tracers. This review summarizes the current state of (18)F-labeled MPI tracers, basic research data of those tracers, and the future direction of MPI tracer research.

Ejemplares similares